High Prevalence of Anti‐Apolipoprotein/A‐1 Autoantibodies in Maintenance Hemodialysis and Association With Dialysis Vintage

Authors:

Abstract
Autoantibodies to apolipoprotein/A‐1 (anti‐ApoA‐1 IgG) have pro‐atherogenic properties in patients at high cardiovascular risk, but its prevalence in patients with end‐stage kidney disease is unknown. The aims of this single‐center, cross‐sectional study were to assess the prevalence of anti‐ApoA‐1 antibodies in patients on maintenance hemodialysis (MHD), and to examine its correlation with inflammatory biomarkers related to atherosclerotic plaque vulnerability and dialysis vintage. To this purpose, anti‐ApoA‐1 IgG levels and the concentrations of interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), monocyte chemoattractant protein‐1 (MCP‐1), metalloproteinase‐9 (MMP‐9), tumor necrosis factor‐α, and C‐reactive protein (CRP) were assessed in the sera of 66 MHD patients (mean age: 68 ± 14 years, 36% women, 32% diabetics). Anti‐ApoA‐1 IgG positivity (defined as a blood value ≥ 97.5th percentile of the normal distribution as assessed in healthy blood donors) was 20%. Circulating levels of anti‐ApoA‐1 IgG correlated positively with dialysis vintage, but not with cardiovascular risk factors or previous cardiovascular events; no significant correlations were found between the anti‐ApoA1 IgG levels and circulating levels of IL‐6, IL‐8, MCP‐1, MMP‐9, CRP, or low‐density lipoprotein‐cholesterol. In multivariable linear regression, adjusted for age and sex, only dialysis vintage remained positively and independently associated with anti‐ApoA‐1 titers (β = 0.05, 95% CI: 0.006; 0.28, P = 0.049). In conclusion, the prevalence of anti‐ApoA‐1 IgG is raised in the MHD‐population, and positively associated with dialysis vintage, a major determinant of cardiovascular outcome. Whether antiApoA‐1 antibodies play a role in the pathophysiology of accelerated atherosclerosis in the MHD‐population merits further study.

This publication has 31 references indexed in Scilit: